Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)
Status and phase
Completed
Phase 1
Conditions
Cytomegalovirus Infections
Treatments
Biological: V160 Low Dose IM
Other: Placebo IM
Biological: V160 Maximum Dose IM
Biological: V160 High Dose IM
Other: Placebo ID
Biological: V160 Medium Dose ID
Biological: V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM
Biological: V160 High Dose plus MAPA 225 µg /dose IM
Biological: V160 Medium Dose IM
Details and patient eligibility
About
This study will evaluate the safety, tolerability, and immunogenicity of various doses, formulations, and routes of administration of Human Cytomegalovirus (HCMV) vaccine V160 administered in a 3-dose regimen in healthy adults. The initial treatment arm of HCMV seropositive participants will receive V160 Low Dose without adjuvant by intramuscular injection. Escalation of the V160 dose, inclusion of adjuvant, administration by intradermal injection, and vaccination of HCMV seronegative participants will be performed only after review of safety data of previous treatment arms. The purpose of the study is to identify vaccine formulations associated with optimal safety profile and HCMV-specific immune response for evaluation in subsequent clinical studies of V160.
Enrollment
190 patients
Sex
All
Ages
18+ years old
Volunteers
Accepts Healthy Volunteers
Inclusion criteria
- Healthy based on medical history and physical examination
- Serologically confirmed to be HCMV seronegative or HCMV seropositive
- Agrees to avoid unusual, unaccustomed strenuous, vigorous physical exercise/activity from 72 hours before through 72 hours after each dose of study vaccine
- Body weight ≥110 lbs (50 kg) and body mass index (BMI) of 19 to 32 kg/m^2
- If of reproductive potential, agrees to the following during the study and for 4 weeks after the last dose of study vaccine: 1) practice abstinence from heterosexual activity, or 2) use or have their partner use 2 allowable methods of birth control during heterosexual activity
Exclusion criteria
- Has previously received any cytomegalovirus vaccine
- Has history of allergic reaction or anaphylactic reaction to any vaccine component that required medical intervention
- Has history of any severe allergic reaction that required medical intervention
- Is pregnant or breastfeeding or expecting to conceive from 2 weeks before the study through 1 month after the last dose of study vaccine
- Plans to donate eggs or sperm from study start through 1 month after the last dose of study drug
- Has impairment of immunologic function including, but not limited to autoimmune disease, splenectomy, or human immunodeficiency virus acquired immunodeficiency syndrome (HIV/AIDS)
- Received systemic corticosteroids for ≥14 consecutive days and has not completed treatment within 30 days of study start
- Received immunosuppressive therapy including, but not limited to rapamycin and equivalents, tacrolimus, FK-506, fujimycin, or other therapies used for solid organ/cell transplant, radiation therapy, immunosuppressive/cytotoxic chemotherapy, or other therapy known to interfere with the immune response within 1 year of study start
- Has a condition in which repeated venipuncture or injections pose more than minimal risk, such as hemophilia, thrombocytopenia or other severe coagulation disorders, or significantly impaired venous access
- Has a condition that requires active medical intervention or monitoring such as diabetes mellitus, autoimmune disease, or a clinically significant chronic medical condition that is considered progressive
- Has history within the past 5 years or current drug or alcohol abuse
- Has major psychiatric illness
- Is legally or mentally incapacitated
- Has participated in another clinical study in the past 4 weeks, or plans during the present study to participate in a treatment-based study or a study in which an invasive procedure is performed
- Has received valganciclovir, ganciclovir, valacyclovir, foscarnet, or cidofovir from 4 weeks prior to 1 month following each V160 vaccination
Trial design
Primary purpose
Prevention
Allocation
Randomized
Interventional model
Parallel Assignment
Masking
Triple Blind
190 participants in 17 patient groups, including a placebo group
HCMV seropositive (+) V160 Low Dose Intramuscular (IM)
Experimental group
Description:
Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
Treatment:
Biological: V160 Low Dose IM
HCMV seronegative (-) V160 Low Dose IM
Experimental group
Description:
Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
Treatment:
Biological: V160 Low Dose IM
HCMV+ V160 Medium Dose IM
Experimental group
Description:
Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
Treatment:
Biological: V160 Medium Dose IM
HCMV- V160 Medium Dose IM
Experimental group
Description:
Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
Treatment:
Biological: V160 Medium Dose IM
HCMV+ V160 High Dose IM
Experimental group
Description:
Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
Treatment:
Biological: V160 High Dose IM
HCMV- V160 Medium Dose plus MAPA 225 µg IM
Experimental group
Description:
Participants seronegative for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6
Treatment:
Biological: V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM
HCMV- V160 High Dose IM
Experimental group
Description:
Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
Treatment:
Biological: V160 High Dose IM
HCMV+ V160 High Dose plus MAPA 225 µg IM
Experimental group
Description:
Participants seropositive for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6
Treatment:
Biological: V160 High Dose plus MAPA 225 µg /dose IM
HCMV+ V160 Maximum Dose IM
Experimental group
Description:
Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
Treatment:
Biological: V160 Maximum Dose IM
HCMV- V160 High Dose plus MAPA 225 µg IM
Experimental group
Description:
Participants seronegative for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6
Treatment:
Biological: V160 High Dose plus MAPA 225 µg /dose IM
HCMV- V160 Maximum Dose IM
Experimental group
Description:
Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
Treatment:
Biological: V160 Maximum Dose IM
HCMV+ Placebo IM
Placebo Comparator group
Description:
Participants seropositive for HCMV at Baseline will receive placebo by IM injection on Day 1, Month 1, and Month 6
Treatment:
Other: Placebo IM
HCMV- Placebo IM
Placebo Comparator group
Description:
Participants seronegative for HCMV at Baseline will receive placebo by IM injection on Day 1, Month 1, and Month 6
Treatment:
Other: Placebo IM
HCMV+ V160 Medium Dose Intradermal (ID)
Experimental group
Description:
Participants seropositive for HCMV at Baseline will receive V160 vaccination by ID injection on Day 1, Month 1, and Month 6
Treatment:
Biological: V160 Medium Dose ID
HCMV- V160 Medium Dose ID
Experimental group
Description:
Participants seronegative for HCMV at Baseline will receive V160 vaccination by ID injection on Day 1, Month 1, and Month 6
Treatment:
Biological: V160 Medium Dose ID
HCMV+ Placebo ID
Placebo Comparator group
Description:
Participants seropositive for HCMV at Baseline will receive placebo by ID injection on Day 1, Month 1, and Month 6
Treatment:
Other: Placebo ID
HCMV- Placebo ID
Placebo Comparator group
Description:
Participants seronegative for HCMV at Baseline will receive placebo by ID injection on Day 1, Month 1, and Month 6
Treatment:
Other: Placebo ID
Trial contacts and locations
0
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems